{"id":124286,"date":"2026-09-02T10:19:16","date_gmt":"2026-09-02T10:19:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/124286\/"},"modified":"2026-09-02T10:19:16","modified_gmt":"2026-09-02T10:19:16","slug":"novartis-halts-eight-car-t-trials-after-three-patient-deaths-biggo-finance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/124286\/","title":{"rendered":"Novartis Halts Eight CAR-T Trials After Three Patient Deaths \u2014 BigGo Finance"},"content":{"rendered":"<p>Novartis AG (NVS) has temporarily suspended eight clinical trials of an experimental cell therapy after three patients died from severe immune reactions, a setback that raises fresh questions about the safety of using CAR-T treatments beyond oncology.<\/p>\n<p>The Swiss drugmaker paused the studies in late August after learning of the deaths, a company spokesperson confirmed. The therapy, known internally as rap-cel, was being investigated for autoimmune and neurological conditions including lupus and multiple sclerosis.<\/p>\n<p>The spokesperson said Novartis is conducting a thorough evaluation of the safety events and noted that fatal immune reactions are a known risk associated with CAR-T therapies. The company is working with independent safety committees overseeing each trial and has notified regulators.<\/p>\n<p>CAR-T, or chimeric antigen receptor T-cell therapy, works by extracting a patient&#8217;s immune cells, genetically modifying them in a laboratory to recognize and destroy abnormal cells, and then reinfusing them. The approach has transformed treatment for certain blood cancers, and pharmaceutical companies have been racing to extend it to autoimmune diseases, where the potential patient population is vastly larger.<\/p>\n<p>That promise now faces renewed scrutiny. The timing of the deaths remains unclear, and Novartis has not disclosed whether investigators have established a causal link between the therapy and the fatalities.<\/p>\n<p>Ripple effects across the industry<\/p>\n<p>The suspension extends beyond Novartis. Bristol Myers Squibb (BMY) said it has paused its own CAR-T program for autoimmune disease, called zola-cel, as a precautionary measure. The New Jersey-based company did not specify when it halted the studies.<\/p>\n<p>The parallel pauses suggest regulators and safety monitors are taking a cautious approach across the entire class of therapies as data on immune-related complications accumulates. For investors, the development introduces uncertainty about development timelines and the commercial viability of CAR-T in autoimmune indications.<\/p>\n<p>The halt also underscores a broader tension in the field: CAR-T therapies have demonstrated remarkable efficacy in cancer, but their safety profile in chronic, non-fatal conditions like lupus faces a higher bar. Patients with autoimmune diseases often have other treatment options, making the risk-benefit calculus fundamentally different from oncology settings.<\/p>\n<p>What comes next<\/p>\n<p>Novartis has not provided a timeline for when the trials might resume. The company said it is collaborating with safety committees and regulators to determine whether protocol changes are needed. The outcome of that review will be closely watched by competitors and investors alike.<\/p>\n<p>Analysts will be looking for details on whether the deaths were related to cytokine release syndrome, a known complication of CAR-T therapy in which the immune system overreacts, or another mechanism. The answers could shape the future of a therapeutic approach that many in the industry view as one of the most promising avenues for treating autoimmune disease.<\/p>\n<p>Note: Suspension figures and company statements are based on information reported by The Wall Street Journal and company disclosures.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG (NVS) has temporarily suspended eight clinical trials of an experimental cell therapy after three patients died&hellip;\n","protected":false},"author":2,"featured_media":124287,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[24061,36657,16181,153,206,1078,40972,60739],"class_list":["post-124286","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-bristol-myers-squibb","tag-car-t-cell-therapy","tag-lupus","tag-multiple-sclerosis","tag-novartis","tag-novartis-ag","tag-rap-cel","tag-zola-cel"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117200942789254863","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=124286"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124286\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/124287"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=124286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=124286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=124286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}